Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 319 Results
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
December 19, 2024
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
December 16, 2024
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
November 25, 2024
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
November 8, 2024
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
November 4, 2024
Inflammatory Disease Healing Data via Palatin’s Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
October 24, 2024
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
October 23, 2024
Palatin Receives Notice of Non-Compliance from NYSE American
October 7, 2024
Page 1 of 32